DOCKET NO.: 279431US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: GROUP: 1612

Tatsuo KIMURA, et al.

SERIAL NO: 10/553,120 EXAMINER: HUANG, G.

FILED: October 14, 2005

FOR: PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING

ALKYL ETHER DERIVATIVES OR SALTS THEREOF

RESTRICTION RESPONSE

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

Sir:

In response to the Restriction Requirement dated May 9, 2008, Applicants elect, with traverse, Group I, Claims 1–4 (in part), for examination. Applicants also provisionally elect, for examination purposes, the specie where:

$$\begin{bmatrix} R^1 & & & \\ & & &$$

R¹ and R² are hydrogen atoms, R³ is OH, m is 2, n is 3, and p is 1 (readable on at least Claims 1-

4). Specifically, said compound is 1-[3-(2-(1-benzothiophen-5-yl)ethoxy)propyl]-3-azetidinol.

Remarks/Arguments begin on page 2 of this paper.